Andere talen Daewoong Pharmaceutical Co., Ltd

Aandelen

A069620

KR7069620003

slotkoers Korea S.E. Andere beurzen 00:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
102.400 ^KRW	+0,89%		+0,20%	-12,33%

14/05	Daewoong Pharmaceutical Co., Ltd rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
24/04	Koreaanse suikerimport daalt met 14% door toename diabetesgevallen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Daewoong Pharmaceutical : Presents Enavogliflozin’s Phase 3 Pooled Analysis Results at 84th ADA Conference	19/06
Daewoong Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Daewoong Pharmaceutical : Reports Q1 2024 Financial Results	30/04
Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	24/04
AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	12/04
AEON Biopharma, Inc. announced that it expects to receive $15 million in funding from Daewoong Pharmaceutical Co., Ltd	19/03
Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia	15/02
Daewoong Pharmaceutical : and Zydus Announce Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S.	11/12
Zydus Worldwide DMCC and Daewoong Pharmaceutical Co., Ltd. Announces Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S	11/12
Daewoong Pharmaceutical : Strikes a $60 Million Deal with JSC Pharmasyntez for Diabetes Novel Drug Enavogliflozin	06/12
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA	28/11
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy	07/11
P.T. Selatox Bio Pharma announced that it expects to receive IDR 200 billion in funding from Daewoong Pharmaceutical Co., Ltd	27-10-23
Daewoong Pharmaceutical : announces ‘3E Global Hyper-Competitive Strategy' at CPHI 2023... Aiming for USD 745M in novel drug sales by 2030	26-10-23
Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market	19-10-23
Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema	25-09-23
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia	30-08-23
Hyphens Pharma International Limited Announces Successful Registration in Malaysia	30-08-23
Daewoong Pharmaceutical : Initiates Global Export of 'Novel Drug'...Launches 'Fexuprazan' in the Philippines	17-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Daewoong Pharmaceutical Co., Ltd

Aandelen

A069620

KR7069620003

Andere talen

Filters